Skip to content

Prescriber Based, Active Post Marketing Surveillance Study (PMS) to Generate The Safety & Efficacy Data Of Diazepam and Propranolol in The Treatment of Chronic Anxiety & Insomnia in Actual Field Conditions Of Use.

Prescriber Based, Active Post Marketing Surveillance Study (PMS) to Generate The Safety & Efficacy Data Of Diazepam and Propranolol in The Treatment of Chronic Anxiety & Insomnia in Actual Field Conditions Of Use.

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/03/023789
Enrollment
200
Registered
2020-03-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F411- Generalized anxiety disorder

Interventions

Intervention1: FDC of Diazepam and Propranolol: Treatment of Chronic anxiety & Insomnia Frequency: Twice a day Dose: Combination of Diazepam 2.5mg and Propanol Hydrochloride 20mg Route of administr

Sponsors

AN Pharmacia Laboratories Pvt ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Both Male and Female patient. 2. Ages: > 18 years and 3. Patients with Chronic Anxiety and Insomnia. 4. Confirmed diagnosis of primary insomnia (as defined by the Diagnostic and Statistical Manual for Mental Disorders-IV [DSM-IV-TR]) present at the time of evaluation for at least 3 months 5. Baseline Hamilton Rating Scale for Anxiety (HAMA) scores >=18 6. Patient with history of primary insomnia 7. Women of child bearing age willing to take contraceptive measure to prevent pregnancy during the study 8. Patients willing to give written informed consent

Exclusion criteria

Exclusion criteria: 1. History of hypersensitivity to the study drugs 2. Chronic heart failure, respiratory failure or chronic liver and renal failure. 3. Patient with active cancer 4. Female who is pregnant, planning a pregnancy (during the course of the study) or nursing a child 5. Certain medications that may interfere with the study medication and worsen the patient condition (these will be identified by the study Investigator). 6. Patients with a history of chronic hepatitis B or C infection, HIV infection. 7. Clinically significant disorder that may unsuitable for study participation.

Design outcomes

Primary

MeasureTime frame
Assessment based on HAMA scale, Clinician Global Impression (CGI) and Patient Global Impression (PGI) scalesTimepoint: 14 days

Secondary

MeasureTime frame
Evaluate efficacy of this FDC in treatment of Chronic Anxiety and Insomnia.Timepoint: 14 days

Countries

India

Contacts

Public ContactDr Nimesh Patel

Sanjeevani Heart & Medical Hosptial

dr_nimesh_patel@yahoo.co.in27641742

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026